The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Open accessAbstract
Purpose: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis. Patients and Methods: We determined the correlation between presence of MYC and BCL2 proteins by immunohistochemistry (IHC) with survival in two independent cohorts of patients with DLBCL treated with R-CHOP. We further determined if MYC protein expression correlated with high MYC mRNA and/or presence of MYC translocation. Results: In the training cohort (n = 167), MYC and BCL2 proteins were detected in 29% and 44% of patients, respectively. Concurrent expression (MYC positive/BCL2 positive) was present in 21% of patients. MYC protein correlated with presence of high MYC mRNA and MYC translocation (both P < .001), but the latter was less frequent (both 11%). MYC protein expression was only associated with inferior overall and progression-free survival when BCL2 protein was coexpressed (P < .001). Importantly, the poor prognostic effect of MYC positive/BCL2 positive was validated in an independent cohort of 140 patients with DLBCL and remained significant (P < .05) after adjusting for presence of high-risk features in a multivariable model that included elevated international prognostic index score, activated B-cell molecular subtype, and presence of concurrent MYC and BCL2 translocations. Conclusion: Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationCamp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Hans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
“In several but not all studies, the double-expressor lymphomas have a worse outcome than other DLBCL, NOS but they are not as aggressive as the HGBL, with rearrangements of MYC and BCL2 and/or BCL6.(69,70) These observations have suggested that double expression of MYC and BCL2 proteins without gene aberrations should…”
Self-citationSehn, L. H., & Salles, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027612 · Cited by 1,175
Self-citationGenetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P. W., Pfreundschuh, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv304 · Cited by 930
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Self-citationDavids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735
“In recent studies, a newly defined subset of “double-hit” DLBCLs which overexpress MYC in association with BCL2 also have an unfavorable outcome (Hu et al., 2013; Johnson et al., 2012).”
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Self-citationLi, S., Young, K. H., & Medeiros, L. J. (2018) · Pathology · doi:10.1016/j.pathol.2017.09.006 · Cited by 649
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Self-citationHorn, H., Ziepert, M., Becher, C., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-435842 · Cited by 542
Self-citationDiffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Petrich, A. M., Gandhi, M., Jovanovic, B., Castillo, J. J., Rajguru, S., Yang, D. T., Shah, K. A., Whyman, J. D., Lansigan, F., Hernandez-Ilizaliturri, F. J., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578963 · Cited by 467
Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., Glass, B., Scott, D. W., Gascoyne, R. D., Connors, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6520 · Cited by 453
Self-citationEnnishi, D., Jiang, A., Boyle, M., Collinge, B., Grande, B. M., Ben-Neriah, S., Rushton, C., Tang, J., Thomas, N., Slack, G. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01583 · Cited by 414
Self-citationDiffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Self-citationScott, D. W., Mottok, A., Ennishi, D., Wright, G. W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G. S., Hother, C., Abrisqueta, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2383 · Cited by 405
Self-citationFriedberg, J. W., & Fisher, R. I. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.002 · Cited by 362
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301077 · Cited by 343
Self-citationRossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Coiffier, B., & Sarkozy, C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.366 · Cited by 292
Pourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310230110 · Cited by 286
Davies, A., Cummin, T. E., Barrans, S., Maishman, T., Mamot, C., Novak, U., Caddy, J., Stanton, L., Kazmi-Stokes, S., McMillan, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30935-5 · Cited by 273
Copie-Bergman, C., Cuillière-Dartigues, P., Baia, M., Briere, J., Delarue, R., Canioni, D., Salles, G., Parrens, M., Belhadj, K., Fabiani, B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647602 · Cited by 255
Ilyas, H., Mikhaeel, N. G., Dunn, J. T., Rahman, F., Møller, H., Smith, D., & Barrington, S. F. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3953-z · Cited by 150
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Schlager, S., Salomon, C., Olt, S., Albrecht, C., Ebert, A., Bergner, O., Wachter, J., Trapani, F., Gerlach, D., Voss, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27506 · Cited by 36
“Among the most frequently rearranged genes are IGH, BCL2, BCL6, and MYC, with 40%, 21%, 19%, and 8% of cases affected, respectively [5–8].”
BackgroundInfluentialIsmail, M. B., Rajendran, P., AbuZahra, H. M., & Veeraraghavan, V. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084259 · Cited by 35
Metadata
- Authors
- Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., Chan, W. C., Iqbal, J., Meyer, P. N., Lenz, G., Wright, G., Rimsza, L. M., Valentino, C., Brunhoeber, P., Grogan, T. M., Braziel, R. M., Cook, J. R., Tubbs, R. R., Weisenburger, D. D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E. S., Staudt, L. M., & Gascoyne, R. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-10-01
- Volume
- 30
- Issue
- 28
- Pages
- 3452-3459
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159862107
- Cited by
- 975
- References
- 43
- FWCI
- 46.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.